Bullatine A

Synonyms: 雪上一枝蒿甲素
Bullatine A 是一种二萜生物碱,作为强效 P2X7 拮抗剂,具有抗风湿、抗炎和抗痛觉作用,可抑制 ATP 诱导的 BV-2 细胞死亡/凋亡 (apoptosis) 以及 P2X 受体介导的炎症反应,通过靶向 SIRT6 抑制胶质瘤细胞生长,特异性地减轻大鼠的痛觉过敏,通过抑制小鼠中的 ROS/JNK/NF-κB 途径减轻 LPS (MS-X54539) 诱导的全身炎症反应,改善慢性社交挫败应激 (CSDS) 小鼠的绝望行为,并可用于炎症、胶质母细胞瘤 (GBM) 和抑郁症研究。
产品编号: MS-Z24141 纯度: 98.0% CAS No.: 1354-84-3 分子式: C22H33NO2 分子量: 343.50
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
询价
200mg
询价
询价

产品描述

Bullatine A 是一种二萜生物碱,作为强效 P2X7 拮抗剂,具有抗风湿、抗炎和抗痛觉作用,可抑制 ATP 诱导的 BV-2 细胞死亡/凋亡 (apoptosis) 以及 P2X 受体介导的炎症反应,通过靶向 SIRT6 抑制胶质瘤细胞生长,特异性地减轻大鼠的痛觉过敏,通过抑制小鼠中的 ROS/JNK/NF-κB 途径减轻 LPS (MS-X54539) 诱导的全身炎症反应,改善慢性社交挫败应激 (CSDS) 小鼠的绝望行为,并可用于炎症、胶质母细胞瘤 (GBM) 和抑郁症研究。

生物实验数据

生物活性 Bullatine A, a diterpenoid alkaloid, is a potent P2X7 antagonist that exhibits anti-rheumatic, anti-inflammatory, and anti-nociceptive effects, inhibits ATP-induced BV-2 cell death/apoptosis as well as P2X receptor-mediated inflammatory responses, suppresses glioma cell growth by targeting SIRT6, specifically alleviates hyperalgesia in rats, attenuates LPS (MS-X54539)-induced systemic inflammatory responses by inhibiting the ROS/JNK/NF-κB pathway in mice, ameliorates despair-like behavior in chronic social defeat stress (CSDS) mice, and can be used for research on inflammation, glioblastoma (GBM), and depression.
IC50 & Target

P2X7 Receptor

 

体外研究
(In Vitro)

Bullatine A (1-50 μM,24 小时) 抑制 ATP 诱导的 BV-2 细胞死亡,下调 IL-6、IL-1β、iNOS 的 mRNA 水平,减少 NO 和 IL-6 的过量产生,并选择性地抑制 BV-2 细胞中 P2X7 受体 mRNA 的上调 (对 P2X4 mRNA 无影响)。
Bullatine A (1-100 μM,6 小时) 以剂量依赖方式刺激原代小胶质细胞中前动力蛋白的表达,EC50 为 3.2 μM。
Bullatine A (10-80 μM,6 小时) 显著抑制 LPS (MS-X54539) 诱导的 BV2 小胶质细胞和 iBMDMs 中 IL-1β、IL-6、iNOS 和 TNF-α 的 mRNA 表达。
Bullatine A (80 μM) 抑制 LPS 诱导的 iBMDMs 中 IKKα/β、IκBα 的磷酸化和 NF-κB p65 的核转位,减少 JNK 磷酸化,但对 p38、ERK1/2 磷酸化无明显影响。
Bullatine A (80 μM,24 小时) 减少 LPS 诱导的 iBMDMs 中细胞内 ROS 生成。
Bullatine A (50-800 nM,7 天) 以剂量依赖方式降低 U87MG 和 U251 细胞的集落形成能力。
Bullatine A (5-45 μM,24 小时) 以剂量依赖方式增加 U87MG 细胞的早期和晚期凋亡率,降低线粒体膜电位,并诱导 U87MG 和 U251 细胞的 G2/M 期细胞周期阻滞。
Bullatine A (5-45 μM,24 小时) 在 U87MG 细胞中下调 p-ERK 和 Myc 的表达并以剂量依赖方式抑制 H3K9Ac、H3K56Ac 的表达,同时上调 SIRT6 的表达。
Bullatine A (50 μM,24 小时) 抑制 eATP 诱导的 BV-2 细胞中线粒体钙超载、ER-线粒体共定位增加、PERK-elF-2α UPR 激活、溶酶体产生、NLRP3 炎症体蛋白表达升高以及细胞存活率降低。

Real Time qPCR

Cell Line: ATP-induced BV-2 cells
Concentration: 1, 10, 50 μM
Incubation Time: 24 h
Result: Up-regulated the ratio of Bcl-2/Bax mRNA.
Down-regulated ATP-induced mRNA levels of IL-6, IL-1β and iNOS in BV-2 cells.
Inhibited ATP-induced up-regulation of P2X7 receptor mRNA without obvious effect on P2X4 mRNA in BV-2 cells.

Real Time qPCR

Cell Line: LPS-induced BV2 microglia and iBMDMs
Concentration: 10, 20, 40, 80 μM
Incubation Time: 6 h
Result: Inhibited LPS (MS-X54539)-induced mRNA expression of IL-1β, IL-6, iNOS and TNF-α in BV2 microglia and iBMDMs.

Cell Cycle Analysis

Cell Line: U87MG and U251 cells
Concentration: 5, 15, 45 μM
Incubation Time: 24 h
Result: Induced G2/M phase cell cycle arrest in U87MG and U251 cells.

Apoptosis Analysis

Cell Line: U87MG cells
Concentration: 5, 15, 45 μM
Incubation Time: 24 h
Result: Increased the early and late apoptosis rates of U87MG cells.
Upregulated the expression of cleaved caspase-9, cleaved caspase-3 and Bax.
Downregulated the expression of Bcl-2.

Western Blot Analysis

Cell Line: U87MG cells
Concentration: 5, 15, 45 μM
Incubation Time: 24 h
Result: Downregulated the expression of p-ERK and Myc proteins in U87MG cells.
Inhibitd the expression of H3K9Ac and H3K56Ac in U87MG cells.
Upregulated the expression of SIRT6.
体内研究
(In Vivo)

Bullatine A (0.3-30 mg/kg,皮下注射,累计剂量每隔 1 小时给药) 以剂量依赖方式减轻脊神经结扎诱导的神经病理性疼痛大鼠和完全弗氏佐剂 (CFA) 诱导的炎性疼痛大鼠的机械性痛觉过敏和热痛觉过敏。
Bullatine A (0.3-30 mg/kg,皮下注射,累计剂量每隔 1 小时给药) 缓解 Walker 256 诱导的骨癌疼痛大鼠和 Streptozotocin (MS-Q80520) 诱导的神经病理性疼痛大鼠的机械性痛觉过敏。
Bullatine A (0.3-30 μg (10 μL),鞘内注射,单次剂量) 抑制神经病理性疼痛大鼠的机械性痛觉过敏。
Bullatine A (5-20 mg/kg,腹腔注射,在 LPS 注射前 12 小时和 1 小时各给药一次) 减轻小鼠中 LPS 诱导的全身炎症反应。
Bullatine A (10 μg/kg,灌胃给药,每日一次,2 周) 改善 CSDS 小鼠的绝望行为。
Bullatine A (10 μg,海马内微注射,每两天一次,10 天) 部分改善海马 MAMs 中 CSDS 诱导的抑郁样行为。

Animal Model: Spinal nerve ligation-induced neuropathic pain model: adult male Wistar rats were subjected to tight ligation of left L5 and L6 spinal nerves under isoflurane anesthesia
Dosage: 0.3, 1, 3, 10, 30 mg/kg
Administration: s.c. cumulative doses at 1 h intervals
Result: Attenuated mechanical allodynia and thermal hyperalgesia in spinal nerve ligation-induced neuropathic pain rats, with ED50 of 1.9 mg/kg and 0.7 mg/kg, Emax of 56.6% MPE and 66.1% MPE respectively.
Animal Model: Diabetic neuropathic pain model: adult male Wistar rats were fasted for 16 h, then received a single intravenous injection of Streptozotocin (40 mg/kg)
Dosage: 0.3, 1, 3, 10, 30 mg/kg
Administration: s.c. cumulative doses at 1 h intervals
Result: Alleviated mechanical allodynia in streptozotocin-induced diabetic neuropathic pain rats, with ED50 of 1.2 mg/kg and Emax of 65.5% MPE.
Animal Model: Complete Freund’s adjuvant (CFA)-induced inflammatory pain model: 100 μL of CFA was injected into the tibiotarsal joint of the left hindpaw of adult male Wistar rats under mild isoflurane anesthesia
Dosage: 0.3, 1, 3, 10, 30 mg/kg
Administration: s.c. cumulative doses at 1 h intervals
Result: Reduced mechanical allodynia and thermal hyperalgesia in CFA-induced inflammatory pain rats, with ED50 of 1.4 mg/kg and 0.6 mg/kg, Emax of 50.2% MPE and 60.2% MPE respectively.
Animal Model: Bone cancer pain model: Adult female Wistar rats were anesthetized with intraperitoneal pentobarbital (50 mg/kg), and 4 × 1050 Walker 256 carcinoma cells in 10 μL phosphate buffer solution were injected into the medullary cavity of the left tibia
Dosage: 0.3, 1, 3, 10, 30 mg/kg
Administration: s.c. cumulative doses at 1 h intervals
Result: Mitigated mechanical allodynia in bone cancer pain rats induced by tibial implantation of Walker 256 carcinoma cells, with ED50 of 0.9 mg/kg and Emax of 45.6% MPE.
Animal Model: Spinal nerve ligation-induced neuropathic pain model: adult male Wistar rats were subjected to tight ligation of left L5 and L6 spinal nerves under isoflurane anesthesia
Dosage: 0.3, 1, 3, 10, 30 μg (10 μL)
Administration: i.t. for a single dose
Result: Inhibited mechanical allodynia in neuropathic pain rats, with ED50 of 1.1 μg and Emax of 55.5% MPE.
Animal Model: C57BL/6 mice (8-10 weeks old, male, 20-25 g) were intraperitoneally injected with 5 mg/kg LPS to induce systemic inflammatory response
Dosage: 5, 10, 20 mg/kg
Administration: i.p., twice at 12 h and 1 h prior to LPS injection
Result: Alleviated LPS-induced liver and lung tissue damage with reduced pathological scores.
Reduced serum IL-6 levels in LPS-treated mice.
Down-regulated mRNA expression of IL-1β, IL-6, iNOS and TNF-α in liver and showed similar trend in lung.
Attenuated immune cell infiltration and structural disruption in liver and lung tissues.
Animal Model: 8-week-old C57BL/6J mice were subjected to chronic social defeat stress (CSDS) for 10 days
Dosage: 10 μg/kg
Administration: i.g. once daily for 2 weeks
Result: Shortened immobility time in forced swimming test (FST) at 10 μg/kg dose, improving despair behavior.
Showed no significant effects on social interaction ratio (SIT), total travel distance in open field test (OFT), or sucrose preference rate (SPT).
Failed to inhibit hippocampal microglia activation induced by CSDS.
Animal Model: 8-week-old C57BL/6J mice underwent hippocampal catheterization surgery, recovered, then were subjected to 10-day CSDS
Dosage: 10 μg
Administration: Intra-hippocampal microinjection every two days for 10 days
Result: Increased social interaction ratio (SIT) and shortened immobility time in FST at 10 μg dose, partially ameliorating depressive-like behaviors.
Showed no significant changes in total travel distance in OFT.
Inhibited the increase of Facl-4 protein in hippocampal mitochondrial-associated ER membranes (MAMs).
Had no significant effect on other MAMs-related proteins (Sigma-1, VDAC, Mfn2).
性状 固体
颜色 White to off-white

化学信息

分子量 343.50
分子式 C22H33NO2
CAS No. 1354-84-3
别名 雪上一枝蒿甲素

储存&溶解度

储存方式

4°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 12.5 mg/mL (36.39 mM; 超声助溶 (<80°C); 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.9112 mL14.5560 mL29.1121 mL72.7802 mL
5 mM0.5822 mL2.9112 mL5.8224 mL14.5560 mL
10 mM0.2911 mL1.4556 mL2.9112 mL7.2780 mL
15 mM0.1941 mL0.9704 mL1.9408 mL4.8520 mL
20 mM0.1456 mL0.7278 mL1.4556 mL3.6390 mL
25 mM0.1164 mL0.5822 mL1.1645 mL2.9112 mL
30 mM0.0970 mL0.4852 mL0.9704 mL2.4260 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

雪上一枝蒿甲素 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础